Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (FR:ALCLS)
:ALCLS
ALCLS Stock Chart & Stats
€3.86
-€0.02(-1.32%)
At close: 4:00 PM EST
€3.86
-€0.02(-1.32%)
Day’s Range― - ―
52-Week Range€1.01 - €4.84
Previous CloseN/A
Volume10.86K
Average Volume (3M)852.48K
Market Cap
€225.66M
Enterprise Value€296.14M
Total Cash (Recent Filing)€190.22M
Total Debt (Recent Filing)€92.78M
Price to Earnings (P/E)117.9
Beta0.56
Next Earnings
Mar 19, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding72,325,455
10 Day Avg. Volume1,338,181
30 Day Avg. Volume852,477
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.16
Price to Sales (P/S)3.65
P/FCF Ratio7.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.88
Revenue Forecast (FY)€54.75M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained, double‑digit revenue expansion indicates expanding demand for Cellectis' products and collaboration services. Durable top‑line momentum supports continued partner funding, milestone receipts and increases likelihood of achieving scale needed to absorb fixed R&D costs over months.
Very High Gross MarginA 92% gross margin implies highly efficient direct cost structure for the company’s core technologies. That structural margin advantage provides long‑term leverage as revenues scale, improving potential to fund R&D and commercial investments while preserving unit economics post‑commercialization.
Proprietary TALEN Tech & Collaboration ModelOwning differentiated TALEN genome‑editing IP plus a collaborator/licensing revenue model creates a durable business mix: non‑dilutive partner funding, milestone cadence and potential royalties. This reduces sole reliance on product sales during clinical development and strengthens long‑term upside.
Bears Say
Negative Profitability MarginsPersistent negative EBIT and net margins show the company has not yet converted scientific progress into profitable operations. Over a multi‑month horizon this reduces retained earnings, increases reliance on external funding, and pressures the timeline for sustainable operating profitability.
Weak Cash GenerationNegative free cash flow growth and poor operating cash conversion indicate the business struggles to turn reported results into usable cash. Structurally weak cash generation raises refinancing and dilution risk and limits the firm's capacity to self‑fund expensive clinical programs.
Increased LeverageA near‑1.0 debt/equity ratio and modest equity base increase financial risk if profits do not materialize. Higher leverage constrains flexibility for R&D or acquisitions, raises interest and refinancing exposure, and can magnify downside during extended development timelines.
Cellectis SA News
ALCLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €1.01 and its highest was €4.84 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €225.66M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Mar 19, 2026 which is today.
How were Cellectis SA’s earnings last quarter?
Currently, no data Available
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.18.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in FR:ALCLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Sensorion SAS
―
Options Prices
Currently, No data available
---